Replimune to Present at Three Upcoming Investor Conferences
March 04 2021 - 8:00AM
Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company
developing oncolytic immuno-gene therapies derived from its
Immulytic™ platform, today announced that members from the
Replimune management team will present and host one-on-one meetings
at the following three virtual investor conferences.
H.C. Wainwright Global Life Sciences Conference Date: March
9-10, 2021Pre-Recorded Formal Presentation will be made live:
Tuesday, March 9, 2021 at 7:00 am ET
Barclays Global Healthcare ConferenceDate: Thursday, March 11,
2021Fireside Chat Presentation Time: 9:10 am ET
33rd Annual Roth ConferenceDate: Wednesday, March 17,
2021Presentation Time: 1:30 pm ET
A simultaneous webcast of the fireside chat presentation at the
Barclays Global Healthcare Conference will be available in the
Investors section of Replimune’s website at www.replimune.com. A
replay will be available for approximately 90 days following the
conference.
About Replimune Replimune Group, Inc.,
headquartered in Woburn, MA, was founded in 2015 to develop the
next generation of oncolytic immune-gene therapies for the
treatment of cancer. Replimune is developing novel, proprietary
therapeutics intended to improve the direct cancer-killing effects
of selective virus replication and the potency of the immune
response to the tumor antigens released. Replimune’s Immulytic™
platform is designed to maximize systemic immune activation, in
particular to tumor neoantigens, through robust viral-mediated
immunogenic tumor cell killing and the delivery of optimal
combinations of immune-activating proteins to the tumor and
draining lymph nodes. The approach is expected to be highly
synergistic with immune checkpoint blockade and other approaches to
cancer treatment across a broad range of cancers. Replimune intends
to progress these therapies rapidly through clinical development in
combination with other immuno-oncology products with complementary
mechanisms of action as well as in standalone indications. For
more information, please visit www.replimune.com.
Investor Inquiries Chris BrinzeyWestwicke, an
ICR Company339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen Goldenberg Verge
Scientific
Communications917.548.1582agoldenberg@vergescientific.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Apr 2023 to Apr 2024